Role of antibody engineering in generation of derivatives starting from MOv19 MAb: 40 years of biological/therapeutic tools against folate receptor alfa.

Frigerio, Barbara; Montermini, Matilde; Silvana, Canevari; Figini, Mariangela

Role of antibody engineering in generation of derivatives starting from MOv19 MAb: 40 years of biological/therapeutic tools against folate receptor alfa.

Frigerio, Barbara; Montermini, Matilde; Silvana, Canevari; Figini, Mariangela.

Afiliação

Frigerio B; Biomarkers Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Montermini M; Biomarkers Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Silvana C; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Figini M; Biomarkers Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.

Antib Ther ; 5(4): 301-310, 2022 Oct.

Article em En | MEDLINE | ID: mdl-36518225